Medical Devices

Prices are adjusted according to historical splits.

EDAP TMS SA Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$394.16 million
Book Value:
Revenue TTM:
$53.36 million
Operating Margin TTM:
Gross Profit TTM:
$18.42 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

EDAP TMS SA had its IPO on 1997-07-31 under the ticker symbol EDAP.

The company operates in the Healthcare sector and Medical Devices industry. EDAP TMS SA has a staff strength of 227 employees.

Stock update

Shares of EDAP TMS SA opened at $10.8 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $10.42 - $11.5, and closed at $10.81.

This is a -2.88% slip from the previous day's closing price.

A total volume of 165,498 shares were traded at the close of the day’s session.

In the last one week, shares of EDAP TMS SA have slipped by -2.35%.

EDAP TMS SA's Key Ratios

EDAP TMS SA has a market cap of $394.16 million, indicating a price to book ratio of 4.8917 and a price to sales ratio of 6.9496.

In the last 12-months EDAP TMS SA’s revenue was $53.36 million with a gross profit of $18.42 million and an EBITDA of $-445750. The EBITDA ratio measures EDAP TMS SA's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, EDAP TMS SA’s operating margin was -4.17% while its return on assets stood at -1.56% with a return of equity of 5.83%.

In Q3, EDAP TMS SA’s quarterly earnings growth was a negative -62.2% while revenue growth was a positive 29.7%.

EDAP TMS SA’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $0.11 per share while it has a forward price to earnings multiple of 38.0228 and a PEG multiple of 90.47. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into EDAP TMS SA’s profitability.

EDAP TMS SA stock is trading at a EV to sales ratio of 5.9585 and a EV to EBITDA ratio of 960.6358. Its price to sales ratio in the trailing 12-months stood at 6.9496.

EDAP TMS SA stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$104.80 million
Total Liabilities
$21.52 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

EDAP TMS SA ended 2023 with $104.80 million in total assets and $0 in total liabilities. Its intangible assets were valued at $104.80 million while shareholder equity stood at $74.24 million.

EDAP TMS SA ended 2023 with $0 in deferred long-term liabilities, $21.52 million in other current liabilities, 74242000.00 in common stock, $0 in retained earnings and $2.41 million in goodwill. Its cash balance stood at $0 and cash and short-term investments were $68.33 million. The company’s total short-term debt was $1,237,000 while long-term debt stood at $4.02 million.

EDAP TMS SA’s total current assets stands at $94.03 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $15.13 million compared to accounts payable of $13.37 million and inventory worth $9.56 million.

In 2023, EDAP TMS SA's operating cash flow was $-18547000.00 while its capital expenditure stood at $594000.

Comparatively, EDAP TMS SA paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

EDAP TMS SA stock is currently trading at $10.81 per share. It touched a 52-week high of $12.65 and a 52-week low of $12.65. Analysts tracking the stock have a 12-month average target price of $13.8.

Its 50-day moving average was $11.35 and 200-day moving average was $9.37 The short ratio stood at 0.64 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 4018.4% are held by institutions.

Frequently Asked Questions About EDAP TMS SA

The stock symbol (also called stock or share ticker) of EDAP TMS SA is EDAP

The IPO of EDAP TMS SA took place on 1997-07-31

Similar Industry Stocks (Medical Devices)

Last Price

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company’s proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.


Parc dActivites la Poudrette-Lamartine, Lyon, France, 69120